CAR T Therapy Case Study Shows Early Success in Treatment of Acute Myeloid Leukemia
A new case study found that an acute myeloid leukemia patient has remained cancer free for 9 months following treatment with the chimeric antigen receptor (CAR) T-cell treatment, CYAD-01, and a bone marrow transplant.
There are currently 2 FDA-approved chimeric antigen receptor (CAR) T-cell therapies available in the United States,
As part of a report by the American Society of Clinical Oncology, Clinical Cancer Advances 2018, CAR T-cell therapy was
In a new phase 1 trial called
A 52-year-old male patient with wild-type AML was enrolled in the THINK trial after receiving initial treatment and relapsing. CYAD-01 treatment was well-tolerated by the patient with non-related adverse events. On disease evaluation day 197 post CYAD-01 treatment, the patient had achieved complete molecular remission. To date, the AML patient has remained cancer-free for 9 months after treatment with CYAD-01, followed by a bone marrow transplant.
“It is important to note that this is the first time CAR T has induced a remission in AML. It is also the first time CAR T has been effective without the need of preconditioning chemotherapy,” said David Sallman, MD, assistant member of the department of malignant hematology at Moffitt and the case study author.
With CAR T-cell treatment, T cells are removed from a patient’s blood and then genetically modified to enable the cells to identify and specifically attack cancer cells. Once the new cells are developed, patients typically receive preconditioning chemotherapy in order to deplete their immune system and make room for the new cells. However, in the THINK study, no preconditioning chemotherapy was necessary.
“Our case study shows that CAR T therapy is a viable option for AML patients,” added Sallman. “We now need to take what we have learned in this initial study and expand the trial.”
Reference
Sallman D, Brayer J, Sagatys E, et al. NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient [published online April 27, 2018]. Haematologica. doi:10.3324/haematol.2017.186742.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
- Around the Helix: Cell and Gene Therapy Company Updates – September 17, 2025
September 17th 2025
- ImmunoLogic, Episode 6: "The Future of Personalized Cancer Vaccines”
September 15th 2025
- Top News in Lymphoma Cell Therapy for World Lymphoma Awareness Day 2025
September 15th 2025